Veraxa Biotech (NASDAQ:VRXA) Share Price Crosses Above 50 Day Moving Average – Here’s What Happened

Veraxa Biotech Holding AG (NASDAQ:VRXA)’s share price passed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $1.24 and traded as high as $1.3298. Veraxa Biotech shares last traded at $1.26, with a volume of 270,102 shares changing hands.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Veraxa Biotech from a “sell” rating to a “hold” rating in a research note on Monday, August 31st.

Veraxa Biotech Price Performance

The stock’s 50-day simple moving average is $1.23.

Insiders Place Their Bets

In other Veraxa Biotech news, Director Oliver Baumann acquired 50,000 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was bought at an average cost of $1.50 per share, with a total value of $75,000.00. Following the completion of the purchase, the director directly owned 5,773,618 shares in the company, valued at $8,660,427. The trade was a 0.87% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christoph Samuel Ziegler bought 30,000 shares of the company’s stock in a transaction on Tuesday, October 20th. The shares were acquired at an average price of $1.09 per share, for a total transaction of $32,700.00. Following the completion of the acquisition, the director owned 37,932 shares in the company, valued at $41,345.88. This represents a 378.21% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 95,000 shares of company stock worth $125,333 in the last three months.

Veraxa Biotech Company Profile

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.